Trial Profile
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Dec 2017
Price :
$35
*
At a glance
- Drugs PF 4447943 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 12 Dec 2017 Results of a study exploring biomarkers that may be informative in demonstrating the pharmacologic effect of PF-04447943 presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 12 Dec 2017 Results assessing safety and tolerability of PF-04447943 across a clinical trial program in 277 patients (Eight phase 1 studies, One phase II and One phase Ib study) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 31 Oct 2016 Status changed from recruiting to completed.